Alzinova: Collaboration to develop innovative diagnostic test - Redeye

Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology. While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated. If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.

Länk till analysen i sin helhet: https://www.redeye.se/research/1159264/alzinova-collaboration-to-develop-innovative-diagnostic-test?utm_source=finwire&utm_medium=RSS